Inhibikase Therapeutics (IKT) Equity Average (2020 - 2026)
Inhibikase Therapeutics (IKT) has 7 years of Equity Average data on record, last reported at $170.3 million in Q1 2026.
- On a quarterly basis, Equity Average rose 88.55% to $170.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $170.3 million, a 88.55% increase, with the full-year FY2025 number at $133.9 million, up 152.99% from a year prior.
- Equity Average reached $170.3 million in Q1 2026 per IKT's latest filing, up from $122.9 million in the prior quarter.
- Over the last five years, Equity Average for IKT hit a ceiling of $170.3 million in Q1 2026 and a floor of $2.3 million in Q3 2024.
- A 5-year average of $47.1 million and a median of $27.3 million in 2022 define the central range for Equity Average.
- Peak YoY movement for Equity Average: plummeted 86.76% in 2024, then soared 3249.76% in 2025.
- Tracing IKT's Equity Average over 5 years: stood at $23.1 million in 2022, then tumbled by 43.7% to $13.0 million in 2023, then skyrocketed by 262.89% to $47.2 million in 2024, then soared by 160.56% to $122.9 million in 2025, then soared by 38.54% to $170.3 million in 2026.
- Business Quant data shows Equity Average for IKT at $170.3 million in Q1 2026, $122.9 million in Q4 2025, and $76.5 million in Q3 2025.